The Biggest Risk for Small Companies – Why Validation Matters
Imagine you’re a small biotech startup with a breakthrough product. You’ve spent years in R&D, securing funding, and preparing for the next stage—scaling up manufacturing. Everything seems to be on track, but there’s one crucial factor that could make or break your company: validation.
Unlike large pharmaceutical giants with decades of credibility and deep pockets, smaller companies don’t have the luxury of absorbing costly compliance mistakes. A single misstep during an FDA audit could result in delays, expensive rework, or, in the worst cases, shutting down entirely.
Through my work in validation, I’ve seen how larger companies leverage their history and established processes to navigate compliance challenges. When the FDA raises a concern, they can point to decades of production data and robust quality systems. Smaller companies, however, don’t have that track record to fall back on. They must demonstrate compliance from the start, proving that their processes are reliable, repeatable, and well-documented.
Without a strong validation strategy, even an innovative product might never reach the market. The cost of addressing compliance issues after the fact can be overwhelming—sometimes too much for a startup to recover from. That’s why small companies need to take validation seriously from day one.
In my conversation with the IP Café podcast, I discussed why startups and smaller manufacturers need to prioritize validation early. If you’re working in the life sciences space, the key takeaway is simple: you can’t afford to get validation wrong.
